WO2005086568A3 - Anticorps anti-icam 1 humains et utilisations de ceux-ci - Google Patents

Anticorps anti-icam 1 humains et utilisations de ceux-ci Download PDF

Info

Publication number
WO2005086568A3
WO2005086568A3 PCT/IB2005/002041 IB2005002041W WO2005086568A3 WO 2005086568 A3 WO2005086568 A3 WO 2005086568A3 IB 2005002041 W IB2005002041 W IB 2005002041W WO 2005086568 A3 WO2005086568 A3 WO 2005086568A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
icam
binding regions
disorders associated
role
Prior art date
Application number
PCT/IB2005/002041
Other languages
English (en)
Other versions
WO2005086568A2 (fr
Inventor
Tobias Litzenburger
Margit Urban
Original Assignee
Morphosys Ag
Tobias Litzenburger
Margit Urban
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag, Tobias Litzenburger, Margit Urban filed Critical Morphosys Ag
Publication of WO2005086568A2 publication Critical patent/WO2005086568A2/fr
Publication of WO2005086568A3 publication Critical patent/WO2005086568A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

La présente invention concerne des régions de liaison antigène, des anticorps et des fragments fonctionnels contenant ces régions de liaison antigène spécifiques de ICAM-1, qui jouent un rôle intégral dans divers troubles ou divers états. Ces anticorps, par conséquent, peuvent être utilisés pour traiter l'arthrite rhumatoïde, le psoriasis, les brûlures dermiques profondes, la rétinopathie diabétique et d'autres troubles divers associés à l'inflammation. Les anticorps de cette invention peuvent aussi être utilisés dans le domaine des diagnostics, ainsi que dans l'investigation du rôle de ICAM-1 dans la progression des troubles associés à un tissu inflammé. Cette invention concerne aussi des séquences d'acides nucléiques codantes pour les anticorps susmentionnés, des vecteurs contenant ceux-ci, des compositions pharmaceutiques et des kits avec des modes d'emploi.
PCT/IB2005/002041 2004-01-26 2005-01-26 Anticorps anti-icam 1 humains et utilisations de ceux-ci WO2005086568A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US53849904P 2004-01-26 2004-01-26
US60/538,499 2004-01-26
US57294804P 2004-05-21 2004-05-21
US60/572,948 2004-05-21

Publications (2)

Publication Number Publication Date
WO2005086568A2 WO2005086568A2 (fr) 2005-09-22
WO2005086568A3 true WO2005086568A3 (fr) 2006-05-04

Family

ID=34976014

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/002041 WO2005086568A2 (fr) 2004-01-26 2005-01-26 Anticorps anti-icam 1 humains et utilisations de ceux-ci

Country Status (1)

Country Link
WO (1) WO2005086568A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0525214D0 (en) 2005-12-12 2006-01-18 Bioinvent Int Ab Biological materials and uses thereof
US20100168392A1 (en) * 2007-08-10 2010-07-01 Wacker Chemie Ag Expression of full length igg and secretion into the culture medium of prokaryotic cells
US8026343B2 (en) 2008-08-08 2011-09-27 Dinona Inc. Antibody modulating the differentiation and function of dendritic cells via binding intercellular adhesion molecule-1 and use thereof
US8623369B2 (en) * 2010-04-27 2014-01-07 National Research Council Of Canada Anti-ICAM-1 single domain antibody and uses thereof
WO2011160078A2 (fr) * 2010-06-17 2011-12-22 The Johns Hopkins University Utilisation de régions variables de chaîne lourde variable dérivées de camélidés ciblant cd18 et icam-1 en tant que microbicide pour prévenir la transmission de vih-1
KR101434029B1 (ko) * 2012-09-14 2014-08-26 서울대학교산학협력단 Ｉｃａｍ－1에 대한 항체 및 그 용도
TWI781108B (zh) * 2016-07-20 2022-10-21 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
WO2018204976A1 (fr) * 2017-05-09 2018-11-15 The Council Of The Queensland Institute Of Medical Research Agents anti-inflammatoires et méthodes de traitement
KR102063341B1 (ko) * 2018-12-31 2020-01-07 다이노나(주) Icam-1에 특이적으로 결합하는 항체 및 그의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035696A2 (fr) * 2001-07-19 2003-05-01 Perlan Therapeutics, Inc. Anticorps humanises

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035696A2 (fr) * 2001-07-19 2003-05-01 Perlan Therapeutics, Inc. Anticorps humanises

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BELLA JORDI ET AL: "The structure of the two amino-terminal domains of human ICAM-1 suggests how it functions as a rhinovirus receptor and as an LFA-1 integrin ligand", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 95, no. 8, 14 April 1998 (1998-04-14), pages 4140 - 4145, XP002368956, ISSN: 0027-8424 *
BOEHNCKE W -H ET AL: "Efficacy of the fully human monoclonal antibody MOR102 (#5) against intercellular adhesion molecule 1 in the psoriasis-severe combined immunodeficient mouse model", BRITISH JOURNAL OF DERMATOLOGY, vol. 153, no. 4, October 2005 (2005-10-01), pages 758 - 766, XP002368881, ISSN: 0007-0963 *
BOEHNCKE W -H ET AL: "Efficacy of the fully human monoclonal antibody MOR102 against ICAM-1 in the psoriasis SCID mouse model", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 123, no. 2, August 2004 (2004-08-01), & 34TH ANNUAL MEETING OF THE EUROPEAN SOCIETY FOR DERMATOLOGICAL RESEARCH (ESDR); VIENNA, AUSTRIA; SEPTEMBER 09-11, 2004, XP009061702, ISSN: 0022-202X *
CASALI P ET AL: "Probing the human B-cell repertoire with EBV: polyreactive antibodies and CD5+ B lymphocytes.", ANNUAL REVIEW OF IMMUNOLOGY. 1989, vol. 7, 1989, pages 513 - 535, XP009061721, ISSN: 0732-0582 *
FRISCH C ET AL: "From EST to IHC: human antibody pipeline for target research", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 275, no. 1-2, 1 April 2003 (2003-04-01), pages 203 - 212, XP004416756, ISSN: 0022-1759 *
KELLERMANN SIRID AIME ET AL: "Antibody discovery: the use of transgenic mice to generate human monoclonal antibodies for therapeutics", CURRENT OPINION IN BIOTECHNOLOGY, LONDON, GB, vol. 13, no. 6, December 2002 (2002-12-01), pages 593 - 597, XP002293544, ISSN: 0958-1669 *
KNAPPIK A ET AL: "Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 296, no. 1, 11 February 2000 (2000-02-11), pages 57 - 86, XP004461525, ISSN: 0022-2836 *
KREBS B ET AL: "High-throughput generation and engineering of recombinant human antibodies", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 254, no. 1-2, 1 August 2001 (2001-08-01), pages 67 - 84, XP004245443, ISSN: 0022-1759 *
LUO G X ET AL: "Humanization of an anti-ICAM-1 antibody with over 50-fold affinity and functional improvement", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 275, no. 1-2, 1 April 2003 (2003-04-01), pages 31 - 40, XP004416747, ISSN: 0022-1759 *

Also Published As

Publication number Publication date
WO2005086568A2 (fr) 2005-09-22

Similar Documents

Publication Publication Date Title
WO2005086568A3 (fr) Anticorps anti-icam 1 humains et utilisations de ceux-ci
WO2006122797A3 (fr) Anticorps anti-gm-csf et leurs utilisations
EA202090227A1 (ru) Анти-lag-3 антитело, обладающее повышенной стабильностью
CY1120384T1 (el) Απταμερη θεραπευτικα χρησιμα στην αντιμετωπιση των σχετικων με το συμπληρωμα διαταραχων
EA200802167A1 (ru) Лекарства и применения
WO2007092772A3 (fr) Formulations de protéines
WO2005103083A3 (fr) Anticorps humains anti-cd38 et utilisations de ceux-ci
MX2008009886A (es) Anticuerpos que enlazan par-2.
MX2012002927A (es) Anticuerpos humanos de alta afinidad con el receptor activado por proteasa humana-2.
NZ591471A (en) Antibodies to ccr2
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
MA33717B1 (fr) Immunoconjugués ciblés
WO2008030611A3 (fr) Anticorps contre les protéines morphogéniques osseuses et les récepteurs de celles-ci et procédés d'utilisation de ceux-ci
TW200745163A (en) Peptides that block the binding of IgG to FcRn
EA200970262A1 (ru) Композиции и способы, относящиеся к антителам к глюкагоновым рецепторам
EA200970113A1 (ru) Бензофуро- и бензотиенопиримидиновые модуляторы гистаминового рецептора н
WO2005097185A3 (fr) Anticorps irta-5 et utilisations de ces derniers
WO2006002262A3 (fr) Genes et voies exprimes de maniere differentielle dans des troubles bipolaires et/ou troubles depressifs majeurs
MX2017013113A (es) Anticuerpos anti-pacap y sus usos.
EA201000424A1 (ru) Антитела к il-23
ATE545422T1 (de) Beta-glycolipide als immunomodulatoren
WO2007012057A3 (fr) Composition a base d'eau de vegetation destinee au traitement d'affections cutanees inflammatoires
TW200801038A (en) Immunoglobulins
WO2007003421A3 (fr) Immunoglobulines
WO2010065536A3 (fr) Antigène-2 du stroma de la moelle osseuse recombinant dans le traitement de maladies auto-immunes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase